Feng Ren

Co-CEO & CSO
Insilico Medicine., Ltd

Dr. Ren Feng graduated from Harvard University with a PhD in Chemistry in 2007 and has over 15 years of experience in the drug discovery industry. He was the head of small molecule innovative drug development for multinational pharmaceutical company GlaxoSmithKline, and successfully developed several clinical candidates and clinical drugs for the treatment of Parkinson's disease, multiple sclerosis, pain, and psoriasis. He joined Shanghai Medicilon in 2018 as Vice President and Senior Vice President, responsible for the R&D service business of the Chemistry and Biology Divisions and the drug discovery platform service business of the company.
In 2021, he joined Insilico Medicine as Chief Scientific Officer, formed and led the Shanghai drug discovery team to build preclinical/clinical product pipeline and external project collaboration using the company's self-developed artificial intelligence platform. Successfully discovered 8 clinical candidate compounds within one year and pushed the company's fastest progressing anti-fibrotic program into the clinical stage. This project is also the first drug candidate developed by AI and entered the clinical stage in China. Published more than 30 international academic papers and 20 international patents. In 2022, Dr. Feng Ren was appointed as Co-Chief Executive Officer of Insilico Medicine.